<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2027-0119</journal-id>
<journal-title><![CDATA[Urología Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Urol. Colomb.]]></abbrev-journal-title>
<issn>2027-0119</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Colombiana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2027-01192025000100033</article-id>
<article-id pub-id-type="doi">10.24875/ruc.24000051</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Disease burden and treatment choice for metastatic hormone-sensitive prostate cancer in Colombia]]></article-title>
<article-title xml:lang="es"><![CDATA[Carga de la enfermedad y elección de tratamiento para el cáncer de próstata metastásico sensible a hormonas en Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Manneh-Kopp]]></surname>
<given-names><![CDATA[Ray]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabrera-Fierro]]></surname>
<given-names><![CDATA[Marino]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ibatá]]></surname>
<given-names><![CDATA[Linda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[Susan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amaya]]></surname>
<given-names><![CDATA[Sandra L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Sociedad de Oncología y Hematología del Cesar Research Center ]]></institution>
<addr-line><![CDATA[ Valledupar]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cancerología Department of Urology ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo Unidad Funcional Clinica de Urología Oncológica, Fundación CTIC]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,EpiThink Health Consulting Department of epidemiology ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
</aff>
<aff id="Af5">
<institution><![CDATA[,Astellas Farma Colombia Medical Affairs ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>33</fpage>
<lpage>43</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2027-01192025000100033&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2027-01192025000100033&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2027-01192025000100033&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  This literature review seeks to understand the landscape of this disease in Colombia (epidemiology, disease burden, diagnosis, and treatment).  Method:  An extensive search for published evidence was carried out, with no date or language limit, in the PUBMED, EMBASE, LILACS, and Scielo databases, gray literature, and administrative databases. The evaluation and selection of studies were carried out by two independent evaluators.  Results:  A total of 1574 references were identified from the PubMed (n = 630), Embase (n = 575), Cochrane Library (n = 335), Scielo (n = 6), and Lilacs (n = 25) databases, and three references were identified by manual search. After removing duplicates, 1157 references were obtained. A total of 921 references were excluded after reading the title and abstract. Two hundred and thirty-six full-text manuscripts were evaluated, and 87 were selected for information extraction. In addition, information was extracted from administrative databases and other sources that reported epidemiological data and treatment patterns of metastatic hormone-sensitive prostate cancer (mHSPC) in Colombia.  Conclusions:  Information regarding the burden, diagnosis, and treatment of mHSPC in Colombia is scarce. In general, the disease burden of mHSPC is underestimated and is of great interest due to its clinical and economic impact. Treatment intensification is implemented in most cases in the country; however, it is mainly performed with chemotherapy. The panorama described invites us to strengthen interventions for timely access and education to physicians in the appropriate treatment of this condition.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Esta revisión de la literatura busca comprender el panorama de esta enfermedad en Colombia (epidemiología, carga de la enfermedad, diagnóstico y tratamiento).  Método:  Se realizó una búsqueda exhaustiva de evidencia publicada, sin límite de fecha o idioma, en las bases de datos de PubMed, Embase, LILACS y SciELO, literatura gris y bases de datos administrativas. La evaluación y selección de los estudios fue realizada por dos evaluadores independientes.  Resultados:  Se identificaron un total de 1.574 referencias provenientes de las bases de datos de PubMed (n = 630), Embase (n = 575), Cochrane Library (n = 335), SciELO (n = 6) y LILACS (n = 25), y tres referencias se identificaron mediante búsqueda manual. Después de eliminar duplicados, se obtuvieron 1.157 referencias. Un total de 921 referencias se excluyeron tras la lectura del título y resumen. Se evaluaron 236 manuscritos completos, de los cuales 87 se seleccionaron para la extracción de información. Adicionalmente, se extrajo información de bases de datos administrativas y otras fuentes que reportaban datos epidemiológicos y patrones de tratamiento de mHSPC en Colombia.  Conclusiones:  La información sobre la carga, diagnóstico y tratamiento del mHSPC en Colombia es escasa. En general, la carga de la enfermedad está subestimada y es de gran interés debido a su repercusión clínica y económica. La intensificación del tratamiento se está implementando en la mayoría de los casos en el país; sin embargo, en su mayoría se realiza con quimioterapia. El panorama descrito invita a fortalecer las intervenciones para el acceso oportuno y la educación de los médicos en el tratamiento adecuado de esta condición.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Prostatic neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Hormone-sensitive prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[Novel hormonal therapy]]></kwd>
<kwd lng="en"><![CDATA[Systemic therapy]]></kwd>
<kwd lng="es"><![CDATA[Neoplasias prostáticas]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de próstata sensible a hormonas]]></kwd>
<kwd lng="es"><![CDATA[Nueva terapia hormonal]]></kwd>
<kwd lng="es"><![CDATA[Terapia sistémica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>International Agency for Research on Cancer, World Health Organization</collab>
<article-title xml:lang=""><![CDATA[Prostate]]></article-title>
<source><![CDATA[GLOBOCAN 2020]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Culp]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Soerjomataram]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Efstathiou]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent global patterns in prostate cancer incidence and mortality rates]]></article-title>
<source><![CDATA[Eur Urol.]]></source>
<year>2020</year>
<numero>77</numero>
<issue>77</issue>
<page-range>38-52</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lowrance]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Breau]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Chou]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chapin]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
<name>
<surname><![CDATA[Crispino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dreicer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2021</year>
<numero>205</numero>
<issue>205</issue>
<page-range>14-21</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pfail]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Montorsi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Galsky]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Oh]]></surname>
<given-names><![CDATA[WK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial]]></article-title>
<source><![CDATA[Prostate Cancer Prostatic Dis.]]></source>
<year>2020</year>
<numero>23</numero>
<issue>23</issue>
<page-range>638-45</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gravis]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Joly]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Oudard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Priou]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Esterni]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Andro-gen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2013</year>
<numero>14</numero>
<issue>14</issue>
<page-range>149-58</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kyriakopoulos]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Carducci]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jarrard]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<numero>36</numero>
<issue>36</issue>
<page-range>1080</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Foulon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carles]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Roubaud]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fléchon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design]]></article-title>
<source><![CDATA[Lancet Lond Engl.]]></source>
<year>2022</year>
<numero>399</numero>
<issue>399</issue>
<page-range>1695-707</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tran]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Matsubara]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Antolin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alekseev]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2019</year>
<numero>20</numero>
<issue>20</issue>
<page-range>686-700</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Sydes]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[NW]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Dearnaley]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Spears]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2016</year>
<numero>387</numero>
<issue>387</issue>
<page-range>1163-77</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Armstrong]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Szmulewitz]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Petrylak]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Holzbeierlein]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Villers]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Azad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer.]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2019</year>
<numero>37</numero>
<issue>37</issue>
<page-range>2974</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[ID]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stockler]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Begbie]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Chowdhury]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enzalutamide with standard first-line therapy in metastatic prostate cancer.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2019</year>
<numero>381</numero>
<issue>381</issue>
<page-range>121-31</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bjartell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira de Santana Gomes]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Given]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Apalutamide for metastatic, castration-sensitive prostate cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2019</year>
<numero>381</numero>
<issue>381</issue>
<page-range>13-24</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sternberg]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[KS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ARASENS: a phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC)]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>2018</year>
<numero>36</numero>
<issue>36</issue>
<page-range>TPS383</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Brawley]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[NW]]></given-names>
</name>
<name>
<surname><![CDATA[Hoyle]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.]]></article-title>
<source><![CDATA[Lancet Lond Engl]]></source>
<year>2018</year>
<numero>392</numero>
<issue>392</issue>
<page-range>2353-66</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[WW]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[HC]]></given-names>
</name>
<name>
<surname><![CDATA[Luk]]></surname>
<given-names><![CDATA[PH]]></given-names>
</name>
<name>
<surname><![CDATA[So]]></surname>
<given-names><![CDATA[TH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer.]]></article-title>
<source><![CDATA[Front Oncol.]]></source>
<year>2021</year>
<numero>11</numero>
<issue>11</issue>
<page-range>627083</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Page]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Boutron]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Mulrow]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The PRISMA 2020 statement: an updated guideline for reporting systematic reviews]]></article-title>
<source><![CDATA[Syst Rev]]></source>
<year>2021</year>
<numero>10</numero>
<issue>10</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parra-Medina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Barahona-Correa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Páyan-Gomez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramirez-Clavijo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fenández-Ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and demographic characteristics of prostate cancer patients in Colombia: data from the national health registry from 2015 to 2019.]]></article-title>
<source><![CDATA[Rev Urol Colomb Urol J.]]></source>
<year>2021</year>
<numero>30</numero>
<issue>30</issue>
<page-range>e204-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Fondo Colombiano de Enfermedades de Alto Costo (CAC).</collab>
<source><![CDATA[ituación del Cáncer en la Población adulta Atendida en el SGSSS de Colombia 2021]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Cuenta de Alto Costo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández Vargas]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Barbosa]]></surname>
<given-names><![CDATA[PX]]></given-names>
</name>
<name>
<surname><![CDATA[Valbuena-Garcia]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Acuña-Merchán]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[González-Diaz]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[National cancer information system within the framework of health insurance in Colombia: a real-world data approach to evaluate access to cancer care]]></article-title>
<source><![CDATA[JCO Glob Oncol]]></source>
<year>2021</year>
<numero>7</numero>
<issue>7</issue>
<page-range>1329-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quiroga]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Citarella]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Senior]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ibatá]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación y Manejo del Cáncer de Próstata Avanzado en Colombia. Enfermedad Ganglionar y Cancer de Próstata Hormonosensible no Metastásico y Metastásico]]></article-title>
<source><![CDATA[Documento de consenso-Parte II.]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Colombiana de Urologia]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salazar Piedrahita]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Villegas Mejia]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Chacon Cardona]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez Villegas]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer survival at Oncologos del Occidente from Colombia, South America]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>2013</year>
<numero>31</numero>
<issue>31</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trinh]]></surname>
<given-names><![CDATA[QD]]></given-names>
</name>
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sandin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Abbott]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cost impact of disease progression to metastatic castration-sensitive prostate cancer]]></article-title>
<source><![CDATA[J Manag Care Spec Pharm]]></source>
<year>2022</year>
<numero>28</numero>
<issue>28</issue>
<page-range>544-54</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niño]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo-Miranda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Amezquita]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lancheros]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Corredor]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Medina]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determination of direct treatment costs of patients with metastatic and nonmetastatic castration-resistant (mCRPC, nmCRPC) and metastatic hormone-sensitive (mHSPC) prostate cancer in Colombia]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2022</year>
<numero>40</numero>
<issue>40</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<collab>National Comprehensive Cancer Network</collab>
<article-title xml:lang=""><![CDATA[Prostate Cancer.]]></article-title>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maluf]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Jr.]]></surname>
<given-names><![CDATA[Serrano Uson PL]]></given-names>
</name>
<name>
<surname><![CDATA[Bastos]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Rodrigues da Rosa]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Wiermann]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consensus for treatment of metastatic castration-sensitive prostate cancer: report from the first global prostate cancer consensus conference for developing countries (PCCCDC).]]></article-title>
<source><![CDATA[JCO Glob Oncol.]]></source>
<year>2021</year>
<numero>7</numero>
<issue>7</issue>
<page-range>550-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jr.]]></surname>
<given-names><![CDATA[Aguiar PN]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Simko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Barreto]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierres]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Giglio]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Jr.]]></surname>
<given-names><![CDATA[Lopes GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer]]></article-title>
<source><![CDATA[Einstein (Sao Paulo)]]></source>
<year>2019</year>
<numero>17</numero>
<issue>17</issue>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kalebasty]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Uchio]]></surname>
<given-names><![CDATA[EM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of advanced prostate cancer in clinical practice: real-world answers to challenging dilemmas.]]></article-title>
<source><![CDATA[JCO Oncol Pract]]></source>
<year>2020</year>
<numero>16</numero>
<issue>16</issue>
<page-range>783-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Cookson]]></surname>
<given-names><![CDATA[MS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.]]></article-title>
<source><![CDATA[Investig Clin Urol]]></source>
<year>2020</year>
<numero>61</numero>
<issue>61</issue>
<page-range>S3-7</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arenas Hoyos]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patrones de Tratamiento en Cáncer de Próstata Metas-tásico Hormonosensible: Datos de un Centro de Referencia de Alta Complejidad en Colombia]]></article-title>
<source><![CDATA[Estudio del Mundo Real (RWE).]]></source>
<year>2022</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Pontificia Universidad Javeriana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<source><![CDATA[MSL VEEVA Engage Information]]></source>
<year>2023</year>
<publisher-loc><![CDATA[United States ]]></publisher-loc>
<publisher-name><![CDATA[VEEVA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cendales]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Yepez]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Data quality at population-based cancer registries in Colombia]]></article-title>
<source><![CDATA[Biomédica]]></source>
<year>2012</year>
<numero>32</numero>
<issue>32</issue>
<page-range>536-44</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murillo]]></surname>
<given-names><![CDATA[RH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tamización del Cáncer de Próstata en Colombia: ¿Es Posible Superar la Controversia?]]></article-title>
<source><![CDATA[Urol Colomb Bogotá En Línea]]></source>
<year>2022</year>
<page-range>3-5</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murad Gutiérrez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bernal Trujillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ucros Rodríguez]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Teranóstico en medicina nuclear: ¿qué es y qué experiencia tenemos en Colombia?]]></article-title>
<source><![CDATA[Rev Colom Radiol]]></source>
<year>2021</year>
<numero>32</numero>
<issue>32</issue>
<page-range>5554-7</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sutera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Eecken]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kishan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hamid]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grist]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Attard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging prognostic groups across the spectrum of metastatic castration-sensitive prostate cancer: disease outcomes and genomics]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2021</year>
<numero>111</numero>
<issue>111</issue>
<page-range>e294-5</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Goldman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tangen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Higano]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Petrylak]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Wilding]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.]]></article-title>
<source><![CDATA[J Clin Oncol.]]></source>
<year>2009</year>
<numero>27</numero>
<issue>27</issue>
<page-range>2450-6</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heesterman]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Van der Poel]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Schoots]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Mehra]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aben]]></surname>
<given-names><![CDATA[KK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.]]></article-title>
<source><![CDATA[BJU Int.]]></source>
<year>2022</year>
<numero>130</numero>
<issue>130</issue>
<page-range>217-25</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Helou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Catton]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Bauman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fazelzad]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Raphael]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abiraterone or docetaxel in men with metastatic castration-sensitive prostate cancer: A pooled analysis of castration resistance-free survival and toxicity]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2018</year>
<numero>36</numero>
<issue>36</issue>
<page-range>354</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heath]]></surname>
<given-names><![CDATA[EI]]></given-names>
</name>
<name>
<surname><![CDATA[Dyson]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Cackowski]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Hafron]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer]]></article-title>
<source><![CDATA[Clin Genitourin Cancer]]></source>
<year>2022</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leith]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ribbands]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Clayton]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gillespie-Akar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[mpact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.]]></article-title>
<source><![CDATA[BMC Urol.]]></source>
<year>2022</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallis]]></surname>
<given-names><![CDATA[CJD]]></given-names>
</name>
<name>
<surname><![CDATA[Malone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cagiannos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Morgan]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Hamilton]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Basappa]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.]]></article-title>
<source><![CDATA[JNCI Cancer Spectr]]></source>
<year>2021</year>
<volume>5</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ramaswamy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sandin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[616P Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2021</year>
<numero>32</numero>
<issue>32</issue>
<page-range>S655-6</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ko]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis]]></article-title>
<source><![CDATA[J Manag Care Spec Pharm]]></source>
<year>2022</year>
<volume>28</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>287-95</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
